Patrick N.
- Country
- Belgium
- Department
- 03204
Research Overview
- Evaluation of Safety and Efficacy of Elacestrant in Combination Therapies for Patients with Metastatic Breast Cancer: A Phase 1b/2 Open-Label Umbrella Study
- Phase 3 Randomized Study of Gedatolisib Combination Therapy versus Standard Endocrine Therapy in HR‑Positive, HER2‑Negative Advanced Breast Cancer Post‑CDK4/6 Inhibitor
- Phase 2 Open‑Label Study of LY3484356 (imlunestrant) versus Tamoxifen or LY3484356 + Goserelin in Premenopausal ER‑Positive HER2‑Negative Early Breast Cancer
Data & Insights
Has run more than one trial at 430 of 769 partner sites.
Specializations
Advanced Breast Cancer Treatment
Specializes in treating hormone receptor-positive (HR+) and HER2-negative breast cancer, with particular emphasis on developing innovative therapeutic approaches for advanced and metastatic cases.
- Endocrine Therapy Combinations
- CDK4/6 Inhibitor Research
- Novel Treatment Strategies
Investigates targeted therapies focusing on ESR1 mutations and resistance mechanisms to conventional treatments.
Specialized Cancer Research
Conducts research in triple-negative breast cancer (TNBC) and explores novel therapeutic combinations involving androgen receptor-positive breast cancers.
- PIK3CA Mutation Studies
- Brain Metastasis Treatment
- Molecular Targeting Approaches
Evaluates novel compounds including selective estrogen receptor degraders (SERDs) and targeted therapeutic agents.
Early-Stage Disease Management
Focuses on adjuvant and neoadjuvant treatment strategies for early-stage breast cancer, with particular attention to hormone receptor-positive disease.
- Extended Endocrine Therapy
- Treatment Resistance
- Disease Recurrence Prevention
Investigates biomarker-driven approaches including ctDNA monitoring for early intervention strategies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.